Protocol Ledger

NCT06223360 · Phase II · ACTIVE NOT RECRUITING

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Interventional Phase II clinical trial protocol NCT06223360 sponsored by Weill Medical College of Cornell University in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-28 Enrollment: 406 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06223360
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)406 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06223360
Protocol FieldVerified Registry Value
NCT IdentifierNCT06223360
Consolidated Lead SponsorWeill Medical College of Cornell University
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment406 participants (ACTUAL)
Registered Start Date2024-03-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI